Drug Safety Data Collection & Evaluation

Published: 23 Mar 2010

Frost & Sullivan is a media partner for this conference, which will present a fresh and original perspective on one of the biggest challenges in the pharmacovigilance world today: gathering critical safety information throughout a drug's lifecycle, from various global departments and functions, and performing an integrated assessment on which to base future decisions.

Industry leaders, academia and regulators will review the latest alterations to the pharmaceutical business model made necessary by growing attention to drug safety concerns, evolving regulatory guidelines, and the solutions to managing ever-growing volumes of data with decreasing budgets and company sizes.

The event will be unique because unlike other general drug safety meetings, which are broadly focused, it will concentrate purely on how data capture and management approaches can be better integrated into the company structure to aid safety decision-making as well as minimise risks to patients and the company.

Why attend?

  • Simplify decision-making throughout a drug's lifecycle by better data collection and evaluation.
  • Build superior drug safety systems and organisational structures to support quick and centralised decision-making.
  • Clarify drug safety roles and responsibilities to enable comprehensive data collection and ensure effective analysis.
  • Discover how to develop strong relationships with external stakeholders and bring outsourced activities in line with company aims.
  • Learn from case studies recently implemented to address challenges in increasing data collection and quality.

Sign in to read the rest of this article

Not signed up? Register now Forgot your password?

Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..